Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Severe Impaired Hepatic Function

NCT06740799 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06740799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06740799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Severe Impaired Hepatic Function
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2024
Completion date
October 31, 2026
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment